Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012

Prodigiosenes for the Treatment of Leukemia

Investigations Regarding the Utility of Prodigiosenes to Treat Leukemia

Deborah A. Smithen,¹ A. Michael Forrester,^{2,6} Dale P. Corkery,³ Graham Dellaire,^{3,4} Julie Colpitts,⁵ Sherri A. McFarland,⁵ Jason N. Berman^{2,5,6} and Alison Thompson¹

Department of Chemistry,¹ Microbiology & immunology,² Biochemistry & Molecular Biology,³ Pathology,⁴ and Pediatrics,⁶ Dalhousie University, P.O. Box 15000, Halifax, Nova Scotia B3H 4R2, Canada Department of Chemistry,⁵ Acadia University, Wolfville, Nova Scotia B4P 2R6, Canada IWK Health Centre,⁷ Halifax, Nova Scotia B3K 6R8, Canada

Alison.Thompson@Dal.Ca

Supporting Information

Table of Contents:

General Experimental	
Zebrafish Husbandry, Embryo Collection & Embryo Staging	4
Xenotransplantation Of Human Leukemia Cells Into Zebrafish Embryos, Diss	ociation, &
Immunolluorescence	
Synthesis of 2-Formyl Pyrroles (5)	6
Synthesis of Dipyrrinones (6)	7
Synthesis of 2-Bromodipyrrins (7)	8
Synthesis of Prodigiosenes (8)	
Synthesis of Diketones 13a and 13b	
NMR Spectra	
2-Formyl Pyrroles (5)	14
4-[2-(Methoxycarbonyl)ethyl]-3,5-dimethyl pyrrole-2-carboxaldehyde (5a)	14
4-[(Methoxycarbonyl)methyl]-3,5-dimethyl pyrrole-2-carboxaldehyde (5b)	14
3-[2-(Methoxycarbonyl)ethyl]-4,5-dimethyl pyrrole-2-carboxaldehyde (5c)	15

4-[(Ethoxycarbonyl)methyl]-3-[2-(methoxycarbonyl)ethyl]-5-methylpyrrole-2-carboxaldehyde (5d)16
Dipyrrinones (6)
(Z)-Methyl 3-(5-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3- yl)propanoate (6a)
(Z)-Methyl 2-(5-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)acetate (6b)
(Z)-Methyl 3-(2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-4,5-dimethyl-1H-pyrrol-3-yl) propanoate (6c)
(Z)-Methyl 3-(4-(2-methoxy-2-oxoethyl)-2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene) methyl)-5-methyl- 1H-pyrrol-3-yl)propanoate (6d)
2-Bromodipyrrins (7)
(Z)-Methyl 3-(5-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)propanoate (7a)
(Z)-Methyl 2-(5-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)acetate (7b).
(Z)-Methyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4,5-dimethyl-1H-pyrrol-3-yl) propanoate (7c)
(<i>Z</i>)-Methyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4-(2-methoxy-2-oxoethyl)-5-methyl-1H-pyrrol-3-yl) propanoate (7d)
Prodigiosenes (8)
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)propanoate (8a)
(Z)-Methyl 2-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate (8b)
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-2H-pyrrol-3-yl)propanoate (8c)
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy-2-oxoethyl)-5-methyl-2H-pyrrol-3-yl)propanoate (8d)
Diketones
Methyl-4,6-Dioxoheptanoate (12)
Methyl-5-Methyl-4,6-Dioxoheptanoate (13a)
Methyl-5-[(Ethoxycarbonyl)Methyl]-4,6-Dioxoheptanoate (13b)29
HPLC Traces
Prodigiosenes (8)
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)propanoate (8a)
(Z)-Methyl 2-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate (8b)

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012

Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-	2H-pyrrol-3-yl)propanoate
(8c)	
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy	v-2-oxoethyl)-5-methyl-2H-
pyrrol-3-yl)propanoate (8d).	
References	

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

General Experimental

All chemicals and reagents were purchased from commercial sources and were used as received, unless otherwise noted. Ethyl acetate, hexanes and dichloromethane were obtained crude and purified via distillation, under air and at 1 atm pressure, before use. HPLC grade methanol, THF and chloroform were employed in reactions where stated. Anhydrous dichloromethane and THF were purchased from EMD Chemicals. Column chromatography was performed using 230-400 mesh Silicycle Ultra Pure Silica Gel, 150 mesh Brockmann III, activated, neutral aluminium oxide or 150 mesh Brockmann III, activated, basic aluminium oxide, as indicated. TLC was performed on silica gel or neutral aluminium oxide plates and visualized using UV light (254 and/or 365 nm) and/or developed with Vanillin stain. Melting points were determined using a Fisher-Johns melting point apparatus and are uncorrected. NMR spectra were recorded using a Bruker AVANCE 500 or a Bruker AC-250 spectrometer. All ¹H and ¹³C NMR chemical shifts are expressed in parts per million (ppm) using the solvent signal [CDCl₃ (¹H 7.26 ppm; ¹³C 77.16 ppm); DMSO (¹H 2.50 ppm; ¹³C 39.52 ppm)] as the internal reference. Splitting patterns are indicated as follows: br, broad; s, singlet; d, doublet; t, triplet; as, apparent singlet; at, apparent triplet; q, quartet; m, multiplet. All coupling constants (J) are reported in Hertz (Hz). Mass spectra were recorded using ion trap (ESI TOF) instruments. UV analysis was carried out using a Varian CARY 100 BIO UV-Visible spectrophotometer; extinction coefficients (ɛ) are reported at the stated λ_{max} (nm) in units of M⁻¹cm⁻¹ in DMSO solvent, with the baseline manually corrected for the solvent. HPLC analysis was performed on a Varian ProStar 410 HPLC autosampler on a Regis[®] Pirkle covalent (R,R) Whelk-01 10/100 FEC, 25 cm x 4.6 mm column.

Zebrafish Husbandry, Embryo Collection & Embryo Staging

Use of zebrafish in this study was approved by the Dalhousie University Animal Care Committee (protocol no. 11-129). Zebrafish were maintained according to standard protocol. Embryos were collected and grown in E3 embryo media (5 mM NaCl, 0.17 mM KCl, 0.4 mM CaCl₂, and 0.16 mM MgSO₄, pH 7.5, supplemented with 1 x 10^{-5} % Methylene Blue [v/v]) at 28.5°C. Embryos completely lacking melanocytes, xanthophores, and iridophores were obtained

through use of *casper* (*roy orbison*^{-/-};*nacre*^{<math>-/-}) double mutant zebrafish line.¹ Embryos were developmentally staged according to standard protocol.²</sup>

Xenotransplantation Of Human Leukemia Cells Into Zebrafish Embryos, Dissociation, & Immunofluorescence

Mutant *casper* zebrafish embryos at 48 hours post fertilization (hpf) were anaesthetized with 0.090 mg/mL Tricaine (Sigma-Aldrich) and used for cell transplantation using a protocol adapted from Haldi et al., (2006)1.^{3,4} Briefly, CM-DiI-labeled K562 cells were loaded into a pulled glass micropipette and 25-50 cells were delivered, as a single injection, into the volk sac of each embryo (Injection conditions: 40ms pulse time, 4.6 psi positive pressure) using a PLI-100 Pressure Injector (Harvard Apparatus, Holliston, MA) while under observation using a Leica MZ16F modular stereomicroscope (Leica Microsystems GmbH, Wetzlar, Germany). Following injection embryos were allowed to recover at 28 °C for 1 hour before transfer to 35 °C where they remained for the experiment. At 24 hours post injection (hpi), only embryos with a uniform fluorescent cell mass at the site of injection were used for proliferation studies. Embryo xenotransplanted with human cancer cells were then maintained in groups of 15-20 within individual Petri dishes prior to drug treatment. At 24 hpi, prodigiosenes were added directly to the fish water, at indicated concentrations, and embryos were incubated for 72 hours until 96 hpi. Embryos treated with 0.3% (v/v) DMSO served as a negative control for drug efficacy. Embryos treated with 20 µM imatinib mesylate (a targeted inhibitor for the BCR-ABL1 oncoprotein in K562 cells) served as a positive control for drug efficacy.⁴ For the fluorescence imaging, a filter with excitation/emission wavelengths of 550/605 nm was used and all embryos were photographed under the same settings. Photographs reported are Z-stack projections: Images were taken at 0.5 micrometer intervals through the entire depth of each embryo and a composite photograph was produced using Zeiss AxioVision computer program (release 4.7.1), using a preprogrammed algorithm.

Prodigiosenes for the Treatment of Leukemia

Experimental Procedures and Data

Synthesis of 2-Formyl Pyrroles (5)

4-[2-(Methoxycarbonyl)ethyl]-3,5-dimethyl pyrrole-2-carboxaldehyde (**5a**).⁵ Following the general procedure for the synthesis of 2-formyl pyrroles (**5**), the title compound was obtained as a yellow solid (2.80 g, 80% yield from **4a**⁶). ¹H NMR (CDCl₃, 250 MHz) δ 9.56 (brs, 1H, NH), 9.46 (s, 1H, CHO), 3.67 (s, 3H, OCH₃), 2.71, (t, 2H, *J* = 7.8 Hz, *CH*₂CH₂CO), 2.45 (t, 2H, *J* = 7.8 Hz, CH₂CH₂CO), 2.28 (s, 3H, CH₃), 2.27 (s, 3H, CH₃) ppm. ¹H NMR matches reported data.⁵

4-[(Methoxycarbonyl)methyl]-3,5-dimethyl pyrrole-2-carboxaldehyde (5b).⁷ Following the general procedure for the synthesis of 2-formyl pyrroles (**5**), the title compound was obtained as a yellow solid (3.70 g, 95% yield from **4b**⁶). ¹H NMR (CDCl₃, 250 MHz) δ 9.69 (brs, 1H, NH), 9.49 (s, 1H, CHO), 3.69 (s, 3H, OCH₃), 3.40, (s, 2H, CH₂CO), 2.29 (s, 6H, 2 x CH₃) ppm. ¹H NMR matches reported data.⁷

3-[2-(Methoxycarbonyl)ethyl]-4,5-dimethyl pyrrole-2-carboxaldehyde (5c).⁵ A solution of dibenzyl oximinomalonate⁵ (4.9 g, 15.6 mmol) in glacial acetic acid (8 mL) was added slowly, over 5 minutes, to a solution of **13a** (3.0 g, 16.1 mmol) in glacial acetic acid (10 mL), with stirring at 70 °C. A mixture of zinc dust (4.09 g, 62.6 mmol) and sodium acetate (1.92 g, 23.5 mmol) were added gradually, so as to maintain a temperature of around 90 °C. After the addition was complete, the reaction mixture was heated at 90 °C, with stirring, for one hour before being allowed to cool, followed by pouring into ice-water (400 mL) and thoroughly extracting with diethyl ether (4 x 200 mL). The combined organic extracts were washed with water (250 mL) and brine (250 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo* to give benzyl 3-(3-methoxy-3-oxopropyl)-4,5-dimethyl-1H-pyrrole-2-carboxylate (**4c**), which was used without further purification. Following the general procedure for the synthesis of 2-formyl pyrroles (**5**), the title compound was obtained as a yellow solid (845 mg, 29% yield from **13a**). ¹H NMR (CDCl₃, 500 MHz) δ 10.03 (br s, 1H, NH), 9.45 (s, 1H, CHO), 3.66 (s, 3H, OCH₃), 3.00 (t, 2H, *J* = 7.9 Hz, *CH*₂CH₂CO₂Me), 2.55 (t, 2H, *J* = 7.9 Hz, CH₂CH₂CO₂Me), 2.23 (s, 3H, CH₃), 1.94 (s, 3H, CH₃) pm; ¹³C NMR (CDCl₃, 125 MHz) δ 176.1, 173.1, 136.3, 134.9, 127.6,

117.8, 51.9, 35.9, 19.6, 11.8, 8.7 ppm; LRMS: 232.1 (M+Na); HRMS: 232.0933 Found, 232.0944 Calculated for $C_{11}H_{15}NO_3Na$. ¹H NMR matches reported data.⁵

4-[(Ethoxycarbonyl)methyl]-3-[2-(methoxycarbonyl)ethyl]-5-methylpyrrole-2-

carboxaldehvde (5d). A solution of dibenzyl oximinomalonate⁵ (4.12 g, 13.16 mmol) in glacial acetic acid (7 mL) was added slowly, over 5 minutes, to a solution of **13b** (3.5 g, 13.55 mmol) in glacial acetic acid (8.5 mL), with stirring at 70 °C. A mixture of zinc dust (3.54 g, 54.2 mmol) and sodium acetate (1.67 g, 20.33 mmol) were added gradually, so as to maintain a temperature of around 90 °C. After the addition was complete, the reaction mixture was heated at 90 °C, with stirring, for one hour before being allowed to cool, followed by pouring into ice-water (400 mL) and thoroughly extracting with diethyl ether (4 x 200 mL). The combined organic extracts were washed with water (250 mL) and brine (250 mL), dried over anhydrous magnesium sulfate and concentrated in vacuo to give benzyl 4-(2-ethoxy-2-oxoethyl)-3-(3-methoxy-3-oxopropyl)-5methyl-1H-pyrrole-2-carboxylate (4d), which was used without further purification. Following the general procedure for the synthesis of 2-formyl pyrroles (5), the title compound was obtained as a yellow solid (917 mg, 26% yield from 13b). M.p. 62-65 °C. ¹H NMR (CDCl₃, 500 MHz) δ 9.75 (br s, 1H, NH), 9.51 (s, 1H, CHO), 4.13 (q, 2H, J = 7.2 Hz, OCH₂CH₃), 3.66 (s, 3H, OCH₃), 3.40 (s, 2H, CH_2CO_2Et), 3.03 (t, 2H, J = 7.8 Hz, $CH_2CH_2CO_2Me$), 2.60 (t, 2H, J = 7.8 Hz, $CH_2CH_2CO_2Me$), 2.28 (s, 3H, CH_3), 1.25 (t, 3H, J = 7.2 Hz, OCH_2CH_3) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 176.6, 173.1, 171.6, 137.3, 135.2, 127.8, 115.3, 61.2, 51.9, 36.3, 30.1, 19.3, 14.4, 12.0 ppm; LRMS: 304.1 (M+Na); HRMS: 304.1163 Found, 304.1155 Calculated for $C_{14}H_{19}NO_5Na$.

Synthesis of Dipyrrinones (6)

(*Z*)-Methyl 3-(5-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-2,4-dimethyl-1Hpyrrol-3-yl)propanoate (6a).⁸ Following the general procedure for the synthesis of dipyrrinones (6), the title compound was obtained as a brown solid (383 mg, 69% yield from 5a). ¹H NMR (CDCl₃, 250 MHz) δ 10.92 (brs, 1H, NH), 10.22 (brs, 1H, NH), 6.35 (s, 1H, *meso*-H), 5.09 (s, 1H), 3.90 (s, 3H, OCH₃), 3.67 (s, 3H, OCH₃), 2.73 (t, 2H, *J* = 7.8 Hz, *CH*₂CH₂CO), 2.44 (t, 2H, *J* = 7.8 Hz, CH₂*CH*₂CO), 2.36 (s, 3H, CH₃), 2.12 (s, 3H, CH₃) ppm. ¹H NMR matches reported data.⁸

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012

(Z)-Methyl 2-(5-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-2,4-dimethyl-1H-

pyrrol-3-yl)acetate (**6b**).⁸ Following the general procedure for the synthesis of dipyrrinones (**6**), the title compound was obtained as a brown solid (1.83 g, 82% yield from **5b**). ¹H NMR (CDCl₃, 250 MHz) δ 10.91 (brs, 1H, NH), 10.31 (brs, 1H, NH), 6.35 (s, 1H, *meso*-H), 5.09 (s, 1H), 3.89 (s, 3H, OCH₃), 3.67 (s, 3H, OCH₃), 3.40 (s, 2H, CH₂CO), 2.37 (s, 3H, CH₃), 2.13 (s, 3H, CH₃) ppm. ¹H NMR matches reported data.⁸

(Z)-Methyl 3-(2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-4,5-dimethyl-1Hpyrrol-3-yl) propanoate (6c). Following the general procedure for the synthesis of dipyrrinones (6), the title compound was obtained as a brown solid (367 mg, 33% yield from 5c). M.p. 225-230 °C. ¹H NMR (CDCl₃, 500 MHz) δ 10.86 (brs, 1H, NH), 10.12 (brs, 1H, NH), 6.34 (s, 1H, *meso*-H), 5.08 (s, 1H, CH), 3.89 (s, 3H, OCH₃), 3.67 (s, 3H, OCH₃), 2.86 (t, 2H, *J* = 8.0 Hz, *CH*₂CH₂CO₂Me), 2.47 (t, 2H, *J* = 8.0 Hz, CH₂CH₂CO₂Me), 2.32 (s, 3H, CH₃), 1.95 (s, 3H, CH₃) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 173.7, 173.4, 168.1, 132.5, 128.6, 122.2, 121.5, 115.9, 100.4, 89.9, 58.3, 51.8, 35.9, 20.4, 11.6, 9.1 ppm; LRMS: 305.1 (M+H); HRMS: 305.1479 Found, 305.1496 Calculated for C₁₆H₂₁N₂O₄.

(Z)-Methyl 3-(4-(2-methoxy-2-oxoethyl)-2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene) methyl)-5-methyl-1H-pyrrol-3-yl)propanoate (6d). Following the general procedure for the synthesis of dipyrrinones (6), the title compound was obtained as a brown solid (204 mg, 20% yield from 5d). M.p. 200-204 °C. ¹H NMR (CDCl₃, 500 MHz) δ 10.88 (brs, 1H, NH), 10.33 (brs, 1H, NH), 6.32 (s, 1H, *meso*-H), 5.09 (s, 1H, CH), 3.90 (s, 3H, OCH₃), 3.67 (s, 6H, 2 x OCH₃), 3.42 (s, 2H, CH₂), 2.88 (t, 2H, *J* = 8.0 Hz, *CH*₂CH₂CO₂Me), 2.51 (t, 2H, *J* = 8.0 Hz, CH₂*CH*₂CO₂Me), 2.37 (s, 3H, CH₃) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 173.7, 173.5, 172.6, 168.2, 133.6, 128.4, 122.8, 121.9, 113.2, 100.1, 90.1, 58.4, 52.2, 51.8, 36.1, 30.3, 20.1, 11.7 ppm; LRMS: 385.1 (M+Na); HRMS: 385.1357 Found, 385.1370 Calculated for C₁₈H₂₂N₂O₆Na.

Synthesis of 2-Bromodipyrrins (7)

(Z)-Methyl 3-(5-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1Hpyrrol-3-yl)propanoate (7a). Following the general procedure for the synthesis of 2bromodipyrrins (7), the title compound was obtained as a yellow solid (343 mg, 52% yield from 6a). M.p. 118-122 °C. ¹H NMR (CDCl₃, 500 MHz) δ 10.2-11.3 (br s, 1H, NH), 6.87 (s, 1H, *meso*-H), 5.58 (s, 1H, CH), 3.83 (s, 3H, OCH₃), 3.66 (s, 3H, OCH₃), 2.71 (t, 2H, J = 7.8 Hz, $CH_2CH_2CO_2Me$), 2.43 (t, 2H, J = 7.8 Hz, $CH_2CH_2CO_2Me$), 2.30 (s, 3H, CH₃), 2.14 (s, 3H, CH₃), ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 173.5, 166.8, 144.0, 137.5, 136.9, 131.4, 126.4, 121.5, 116.3, 99.3, 58.5, 51.7, 34.8, 19.7, 12.3, 9.6 ppm; LRMS: 367.1 (M+H); HRMS: 367.0653 Found, 367.0652 Calculated for C₁₆H₂₀N₂O₃Br.

(Z)-Methyl 2-(5-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1Hpyrrol-3-yl)acetate (7b). Following the general procedure for the synthesis of 2-bromodipyrrins (7), the title compound was obtained as a yellow solid (414 mg, 72% yield from 6b). M.p. 129-133 °C. ¹H NMR (CDCl₃, 500 MHz) δ 6.88 (s, 1H, *meso*-H), 5.58 (s, 1H, CH), 3.83 (s, 3H, OCH₃), 3.67 (s, 3H, OCH₃), 3.38 (s, 2H, CH₂CO), 2.31 (s, 3H, CH₃), 2.15 (s, 3H, CH₃) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 172.1, 167.0, 144.7, 138.1, 137.4, 131.1, 126.4, 116.5, 115.8, 99.5, 58.6, 52.2, 30.3, 12.5, 9.8 ppm; LRMS: 353.0 (M+H); HRMS: 353.0489 Found, 353.0495 Calculated for C₁₅H₁₈N₂O₃.

(Z)-Methyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4,5-dimethyl-1Hpyrrol-3-yl) propanoate (7c). Following the general procedure for the synthesis of 2bromodipyrrins (7), the title compound was obtained as an orange solid (198 mg, 48% yield from 6c). M.p. 100-104 °C. ¹H NMR (CDCl₃, 500 MHz) δ 6.87 (s, 1H, *meso*-H), 5.58 (s, 1H, CH), 3.83 (s, 3H, OCH₃), 3.66 (s, 3H, OCH₃), 2.87 (t, 2H, *J* = 7.9 Hz, *CH*₂CH₂CO₂Me), 2.49 (t, 2H, *J* = 7.9 Hz, CH₂*CH*₂CO₂Me), 2.27 (s, 3H, CH₃), 1.95 (s, 3H, CH₃) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 173.3, 167.1, 144.3, 137.8, 137.2, 134.0, 125.9, 118.3, 116.3, 99.4, 58.6, 51.9, 35.7, 20.3, 12.5, 9.0 ppm; LRMS: 367.1 (M+H); HRMS: 367.0635 Found, 367.0652 Calculated for C₁₆H₂₀N₂O₃Br.

(Z)-Methyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4-(2-methoxy-2oxoethyl)-5-methyl-1H-pyrrol-3-yl) propanoate (7d). Following the general procedure for the synthesis of 2-bromodipyrrins (7), the title compound was obtained as a dark yellow oil (153 mg, 69% yield from 6d). ¹H NMR (CDCl₃, 500 MHz) δ 6.85 (s, 1H, *meso*-H), 5.55 (s, 1H, CH), 3.82 (s, 3H, OCH₃), 3.66 (s, 3H, OCH₃), 3.64 (s, 3H, OCH₃), 3.39 (s, 2H, CH₂), 2.88 (t, 2H, *J* = 8.0 Hz, *CH*₂CH₂CO₂Me), 2.88 (t, 2H, *J* = 8.0 Hz, CH₂CH₂CO₂Me), 2.29 (s, 3H, CH₃) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 173.2, 172.0, 167.2, 145.5, 137.9, 137.9, 133.7, 126.0, 116.0, 115.2,

99.7, 58.6, 52.2, 51.8, 36.0, 30.1, 20.0, 12.5 ppm; LRMS: 426.1 (M+H); HRMS: 425.0688 Found, 425.0707 Calculated for $C_{18}H_{22}N_2O_5Br$.

Synthesis of Prodigiosenes (8)

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2Hpyrrol-4-yl)propanoate (8a). Following the general procedure for the synthesis of prodigiosenes (8), the title compound was obtained as a deep red solid (79 mg, 55% yield from 7a). M.p. 78-83 °C. ¹H NMR (CDCl₃, 500 MHz) δ 6.89 (s, 1H, *meso*-H), 6.65 (d, 1H, *J* = 2.5 Hz, PyH), 6.60 (as, 1H, PyH), 6.11 (t, 1H, *J* = 2.5 Hz, PyH), 6.08 (s, 1H, PyH), 3.97 (s, 3H, OCH₃), 3.56 (s, 3H, OCH₃), 2.56 (t, 2H, *J* = 7.8 Hz, *CH*₂CH₂CO₂Me), 2.32 (t, 2H, *J* = 7.8 Hz, CH₂*CH*₂CO₂Me), 2.11 (s, 3H, CH₃), 1.70 (s, 3H, CH₃); ¹³C NMR (CDCl₃, 125 MHz) δ 173.8, 168.9, 159.1, 137.0, 129.7, 128.7, 125.7, 122.8, 120.7, 113.4, 112.43, 112.36, 110.0, 95.5, 58.6, 51.7, 35.0, 19.9, 10.3, 9.8 ppm; LRMS: 354.2 (M+H); HRMS: 354.1789 Found, 354.1812 Calculated for C₂₀H₂₄N₃O₃; ε _{476nm} = 33,300; HPLC analysis: 96%.

(Z)-Methyl 2-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2Hpyrrol-4-yl)acetate (8b). Following the general procedure for the synthesis of prodigiosenes (8), the title compound was obtained as a deep red solid (124 mg, 65% yield from 7b). M.p. 68-72 °C. ¹H NMR (CDCl₃, 500 MHz) δ 6.87 (s, 1H, *meso*-H), 6.70 (as, 1H, PyH), 6.66 (d, 1H, *J* = 4.0 Hz, PyH), 6.17 (t, 1H, *J* = 3.0 Hz, PyH), 6.03 (s, 1H, PyH), 3.95 (s, 3H, OCH₃), 3.63 (s, 3H, OCH₃), 3.28 (s, 2H, CH₂CO), 2.14 (s, 3H, CH₃), 1.89 (s, 3H, CH₃); ¹³C NMR (CDCl₃, 125 MHz) δ 172.3, 168.9, 159.3, 137.8, 137.2, 130.0, 128.7, 125.7, 122.7, 114.8, 113.4, 112.4, 110.0, 95.5, 58.5, 51.99, 30.3, 10.5, 9.8 ppm; LRMS: 340.2 (M+H); HRMS: 340.1667 Found, 340.1656 Calculated for C₁₉H₂₂N₃O₃; ε_{472nm} = 41,700; HPLC analysis: 99%.

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-2Hpyrrol-3-yl)propanoate (8c). Following the general procedure for the synthesis of prodigiosenes (8), the title compound was obtained as a deep red solid (52 mg, 54% yield from 7c). M.p. 51-56 °C. ¹H NMR (CDCl₃, 500 MHz) δ 6.88 (s, 1H, *meso*-H), 6.66-6.67 (m, 2H, 2 x PyH), 6.14 (ad, 1H, *J* = 2.5 Hz, PyH), 6.06 (s, 1H, PyH), 3.97 (s, 3H, OCH₃), 3.66 (s, 3H, OCH₃), 2.86 (t, 2H, *J* = 7.9 Hz, *CH*₂CH₂CO₂Me), 2.45 (t, 2H, *J* = 7.9 Hz, CH₂CH₂CO₂Me), 1.82 (s, 3H, CH₃), 1.75 (s, 3H, CH₃); ¹³C NMR (CDCl₃, 125 MHz) δ 173.4, 168.6, 158.1, 137.3, 131.5, 128.4, 125.0, 123.0, 117.6, 112.9, 112.63, 112.56, 110.1, 95.3, 58.5, 51.7, 35.7, 20.3, 10.5, 8.9 ppm; LRMS: 354.2 (M+H); HRMS: 354.1793 Found, 354.1812 Calculated for $C_{20}H_{24}N_3O_3$; $\varepsilon_{478nm} = 40,200$; HPLC analysis: 99%.

(*Z*)-Methyl **3**-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy-2-oxoethyl)-5-methyl-2H-pyrrol-3-yl)propanoate (8d). Following the general procedure for the synthesis of prodigiosenes (8), the title compound was obtained as a deep red solid (34 mg, 37% yield from 7d). M.p. 40-45 °C. ¹H NMR (CDCl₃, 500 MHz) δ 6.85 (s, 1H, *meso*-H), 6.67-6.80 (m, 2H, PyH), 6.15 (at, 1H, *J* = 3.0 Hz, PyH), 6.05 (s, 1H, PyH), 3.96 (s, 3H, OCH₃), 3.66 (s, 3H, OCH₃), 3.62 (s, 3H, OCH₃), 3.29 (s, 2H, *CH*₂CO₂Me), 2.89 (t, 2H, *J* = 8.0 Hz, *CH*₂CH₂CO₂Me), 2.51 (t, 2H, *J* = 8.0 Hz, CH₂CH₂CO₂Me), 1.80 (s, 3H, CH₃); ¹³C NMR (CDCl₃, 125 MHz) δ 173.6, 172.3, 169.0, 139.2, 137.3, 132.1, 128.4, 125.5, 123.2, 114.5, 113.11, 113.09, 112.8, 110.3, 95.7, 58.6, 52.2, 51.8, 36.1, 30.2, 20.1, 10.8 ppm; LRMS: 412.2 (M+H); HRMS: 412.1870 Found, 412.1867 Calculated for C₂₂H₂₆N₃O₅; ϵ_{470nm} = 30,000; HPLC analysis: 99%.

Synthesis of Diketones 13a and 13b

Methyl-4,6-Dioxoheptanoate (12).⁵ a) Carbon tetrachloride (0.2 mL, ~2 mmol) was added drop-wise to a suspension of magnesium turnings (4.0 g, 164.4 mmol) in HPLC grade methanol (15 mL), with stirring under N₂, and the mixture was warmed until evolution of H₂ gas commenced (~30 °C). Additional methanol (50 mL) was added slowly and heating was continued, increasing to 50 °C, until the magnesium had completely dissolved (~2 hours). [']Butylacetoacetate (9, 26.7 mL, 161.2 mmol) was then added over 15 minutes and the resulting reaction mixture was heated to reflux temperature for 1 hour, after which time the reaction mixture was cooled to r.t. and filtered, washing with methanol, and then dried under vacuum. b) 3-Methoxycarbonyl propionyl chloride was added over 15 minutes to a stirred suspension of the product (10) from part a), above, in diethyl ether (75 mL) and the reaction mixture was heated to reflux temperature the reaction hindered stirring, therefore a couple of boiling chips were added. After 30 minutes the reaction was cooled to 0 °C and acidified slowly with 2 M aqueous H₂SO₄ (~40 mL), until the residue had completely dissolved. The two layers were then separated and the aqueous phase was extracted with ether (3 x 60 mL). The organic extracts were combined and washed with water (3 x 100 mL), dried over anhydrous

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

magnesium sulfate, filtered and concentrated to give a pale yellow oil, which was used in part c), below, without further purification. c) *p*-Tosic acid (150 mg, 0.8 mmol) was added to the crude product (**11**) from part b), above, and the neat mixture was heated to reflux temperature (~160 °C) for 1 hour, until gas evolution had ceased. The reaction mixture was then cooled to r.t., dissolved in diethyl ether (100 mL) and extracted quickly with ice-cold NaOH solution (2 M, 35 mL then 3 x 20 mL). The aqueous extracts were run directly into ice-cold sulphuric acid solution (2 M, 80 mL), which was, in turn, extracted with dichloromethane (3 x 80 mL). The organic extracts were combined and washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified by distillation under reduced pressure (aspirator, head temp. ~120 °C) to give *methyl-4,6-dioxoheptanoate* **12** (10.83 g, 39% yield) as a clear colourless oil. ¹H NMR (CDCl₃, 250 MHz) δ (enol tautomer) 15.11 (brs, 1H, OH), 5.48 (s, 1H, CH), 3.64 (s, 3H, OCH₃), 2.61-2.58 (m, 4H, CH₂CH₂), 1.98 (s, 3H, CH₃C=C); (keto tautomer) 3.62 (s, 3H, OCH₃), 3.59 (s, 2H, CH₂), 2.77 (t, 2H, *J* = 6.5 Hz, CH₂), 2.61-2.58 (m, 2H, CH₂), 2.20 (s, 3H, CH₃CO) ppm. The keto:enol ratio was estimated to be 1:3.

Methyl-5-Methyl-4,6-Dioxoheptanoate (**13a**).⁵ Iodomethane (2.4 mL, 38.3 mmol) was added drop-wise to a vigorously stirred suspension of methyl-4,6-dioxoheptanoate (**12**, 5.5 g, 31.9 mmol) and potassium carbonate (4.41 g, 31.9 mmol) in acetone (75 mL). The flask was then fitted with a large condenser and the reaction heated to 80 °C, with vigorous stirring overnight. After cooling slightly the reaction mixture was filtered whilst still hot, washing with acetone, and then concentrated. The residue was then dissolved in chloroform (50 mL) and washed with water (2 x 30 mL) and brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified via distillation under reduced pressure (vacuum pump, head temp. ~84 °C) to give *methyl-5-methyl-4,6-dioxoheptanoate* (**13a**, 5.16 g, 87% yield) as a colourless oil. ¹H NMR (CDCl₃, 250 MHz) δ (enol tautomer) 3.67 (s, 3H, OCH₃), 2.70-2.80 (m, 2H, CH₂CH₂CO₂Me), 2.55-2.65 (m, 2H, *CH*₂CH₂CO₂Me), 2.12 (s, 3H, CH₃CO), 1.35 (s, 3H, CH₃C=C); (keto tautomer) 3.71 (q, 1H, *J* = 7.0 Hz, *CH*CH₃), 3.64 (s, 3H, OCH₃), 2.70-2.80 (m, 2H, CH₂*CH*₂CO₂Me), 2.55-2.65 (m, 2H, *CH*₂CH₂CO₂Me), 2.18 (s, 3H, CH₃CO), 1.32 (d, 3H, *J* = 7.0 Hz, CH*CH*₃) ppm. The keto:enol ratio was estimated to be 3:1.

Methyl-5-[(Ethoxycarbonyl)Methyl]-4,6-Dioxoheptanoate (13b).⁵ Methyl-4,6-Dioxoheptanoate (12, 5.0 g, 29.0 mmol) was added dropwise to a vigorously stirred suspension of potassium carbonate (4.41 g, 31.9 mmol) in acetone (70 mL) and the resulting mixture was heated to gentle reflux (~55 °C), during which time ethyl bromoacetate (4.5 mL, 40.7 mmol) was added dropwise. Following the addition, the reaction mixture was heated to 75 °C with vigorous stirring for 5 hours. After cooling slightly the reaction mixture was filtered whilst still hot, washing with acetone, and then concentrated. The residue was then dissolved in chloroform (50 mL) and washed with water (2 x 30 mL) and brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified via distillation under reduced pressure (vacuum pump, head temp. ~140 °C) to give *methyl-5-[(ethoxycarbonyl)methyl]-4,6-dioxoheptanoate* (**13b**) (5.67 g, 76% yield) as a pale yellow oil. ¹H NMR (CDCl₃, 250 MHz) δ (enol tautomer) 4.04 (q, 2H, *J* = 7.0 Hz, *CH*₂CH₃), 3.59 (s, 3H, OCH₃), 3.19 (s, 2H, CH₂C=C), 2.80-2.90 (m, 2H, CH₂CH₂CO₂Me), 2.55-2.65 (m, 2H, *CH*₂CH₂CO₂Me), 2.12 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₃); (keto tautomer) 4.09-4.18 (m, 1H, *CH*CH₂), 4.04 (q, 2H, *J* = 7.0 Hz, *CH*₂CH₃CO₂Me), 2.80-2.84 (m, 2H, CH*C*H₂), 2.50-2.60 (m, 2H, *CH*₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, *CH*₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₂CO₂Me), 2.21 (s, 3H, CH₃CO), 1.17 (t, 3H, *J* = 7.0 Hz, CH₂CH₃) ppm. The keto:enol ratio was estimated to be 1:1.

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

NMR Spectra

2-Formyl Pyrroles (5)

4-[2-(Methoxycarbonyl)ethyl]-3,5-dimethyl pyrrole-2-carboxaldehyde (5a).

¹H NMR (CDCl₃, 250 MHz):



4-[(Methoxycarbonyl)methyl]-3,5-dimethyl pyrrole-2-carboxaldehyde (5b).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

3-[2-(Methoxycarbonyl)ethyl]-4,5-dimethyl pyrrole-2-carboxaldehyde (5c).



4-[(Ethoxycarbonyl)methyl]-3-[2-(methoxycarbonyl)ethyl]-5-methylpyrrole-2-

carboxaldehyde (5d).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

Dipyrrinones (6)

(Z)-Methyl 3-(5-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-2,4-dimethyl-1H-

pyrrol-3-yl)propanoate (6a).

¹H NMR (CDCl₃, 250 MHz):



(Z)-Methyl 2-(5-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-2,4-dimethyl-1H-

pyrrol-3-yl)acetate (6b).



Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-4,5-dimethyl-1H-

pyrrol-3-yl) propanoate (6c).





(Z)-Methyl 3-(4-(2-methoxy-2-oxoethyl)-2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)

methyl)-5-methyl-1H-pyrrol-3-yl)propanoate (6d).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

2-Bromodipyrrins (7)

(Z)-Methyl 3-(5-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1H-

pyrrol-3-yl)propanoate (7a).



Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 2-(5-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1H-

pyrrol-3-yl)acetate (7b).



Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4,5-dimethyl-1H-

pyrrol-3-yl) propanoate (7c).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4-(2-methoxy-2-

oxoethyl)-5-methyl-1H-pyrrol-3-yl) propanoate (7d).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

Prodigiosenes (8)

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-

pyrrol-4-yl)propanoate (8a).



Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 2-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-

pyrrol-4-yl)acetate (8b).



Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-2H-

pyrrol-3-yl)propanoate (8c).



Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy-2-

oxoethyl)-5-methyl-2H-pyrrol-3-yl)propanoate (8d).





Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

Diketones

Methyl-4,6-Dioxoheptanoate (12).





Methyl-5-Methyl-4,6-Dioxoheptanoate (13a).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012

Prodigiosenes for the Treatment of Leukemia

Methyl-5-[(Ethoxycarbonyl)Methyl]-4,6-Dioxoheptanoate (13b).



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2012 Prodigiosenes for the Treatment of Leukemia

HPLC Traces

Prodigiosenes (8)

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-

pyrrol-4-yl)propanoate (8a).



Solvent: Methanol:Water:NH₄OH ratio 90:9.8:0.2 15 μ L injection Flow rate: 0.75 mL/min Detector: 451 nm Retention time: 29.9 minutes Result: 96%

(Z)-Methyl 2-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-

pyrrol-4-yl)acetate (8b).



Solvent: Methanol:Water:NH₄OH ratio 90:9.8:0.2 15 μ L injection Flow rate: 0.75 mL/min Detector: 451 nm Retention time: 23.3 minutes Result: 99%

Prodigiosenes for the Treatment of Leukemia

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-2H-

pyrrol-3-yl)propanoate (8c).



Solvent: Methanol:Water:NH₄OH ratio 90:9.8:0.2 15 μ L injection Flow rate: 0.75 mL/min Detector: 451 nm Retention time: 27.3 minutes Result: 99%

(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy-2-



oxoethyl)-5-methyl-2H-pyrrol-3-yl)propanoate (8d).

Solvent: Methanol:Water:NH₄OH ratio 90:9.8:0.2 15 μ L injection Flow rate: 0.75 mL/min Detector: 451 nm Retention time: 19.1 minutes Result: 99%

References

(1) White, R. M.; Sessa, A.; Burke, C.; Bowman, T.; LeBlanc, J.; Ceol, C.; Bourque, C.; Dovey, M.; Goessling, W.; Burns, C. E.; Zon, L. I. *Cell Stem Cell* 2008, *2*, 183.

(2) Kimmel, C. B.; Ballard, W. W.; Kimmel, S. R.; Ullmann, B.; Schilling, T. F. *Dev Dyn* 1995, *203*, 253.

(3) Haldi, M.; Ton, C.; Seng, W. L.; McGrath, P. Angiogenesis 2006, 9, 139.

(4) Corkery, D. P.; Dellaire, G.; Berman, J. N. Br. J. Haematol. 2011, 153, 786.

(5) Lash, T. D.; Mani, U. N.; Lyons, E. A.; Thientanavanich, P.; Jones, M. A. J. Org. Chem. 1999, 64, 478.

- (6) Paine III, J. B.; Dolphin, D. J. Org. Chem. 1985, 50, 5598.
- (7) Smith, K. M.; Eivazi, F.; Martynenko, Z. J. Org. Chem. 1981, 46, 2189.
- (8) Regourd, J.; Al-Sheikh Ali, A.; Thompson, A. J. Med. Chem. 2007, 50, 1528.